COVID-19 Clinical Resources and Pertinent Research
A regularly updated list of the most useful COVID-19 clinical resources, the most significant research publications, and reliable news. To contribute, click the plus button on the left. Short URL: bit.ly/C19Res

Treatment and Management Research

  1. Resources
    1. Assessment of Evidence for COVID-19-Related Pharmacological Treatments
    2. NIH COVID-19 Treatment Guidelines (Rx Summary)
    3. BMJ Living WHO Guideline on Drugs for COVID-19
    4. IDSA Overview of COVID-19 Treatment Guidelines (Image Format)
    5. BMJ Drug Treatments for COVID-19: Living Systematic Review and Network Meta-Analysis
    6. JAMA Review Pathophysiology, Transmission, Diagnosis, and Treatment of COVID-19 (7/20)
    7. UW COVID-19 Treatment, Trails, and Teaching Guide
    8. Global Coronavirus COVID-19 Clinical Trial Tracker

  2. Clinical Management
    1. NIH Summary of Recommendations for the Care of Critically Ill Patients With COVID-19
    2. Systemic Anticoagulation is Associated with Lower Mortality and Intubation Among Hospitalized Patients
    3. Pathogenesis of Cytokine Storm in COVID-19
    4. Prone Positioning May Improve Oxygenation in Select Patients
    5. Cardiopulmonary Resuscitation is Ineffective in Hospitalized COVID-19 Patients in Cardiac Arrest
    6. Other
  3. SARS-CoV-2-Specific Monoclonal Antibodies (mAbs)
    1. Bamlanivimab (LY-CoV555)
      1. NIH Recommendations on the Use of Bamlanivimab for the Treatment of COVID-19
      2. IDSA Recommends Against the Routine Use of Bamlanivimab in Ambulatory COVID-19 Patients
      3. FDA Bamlanivimab Fact Sheet for Health Care Providers
      4. PulmCrit, REBEL EM, and JAMA Summaries of Bamlanivimab Data
      5. Preliminary Findings – Ineffective As Monotherapy for the Treatment of COVID-19
    2. Casirivimab/Imdevimab (REGN10933/REGN10987; REGN-COV2)
      1. NIH Recommendations on the Use of Casirivimab/Imdevimab for the Treatment of COVID-19
      2. FDA Casirivimab/Imdevimab Fact Sheet for Health Care Providers
      3. Preliminary Findings
    3. See ASHP’s Assessment of Evidence for COVID-19-Related Treatments – SARS-CoV-2-Specific Monoclonal Antibodies

  4. Convalescent Plasma
    1. Little to No Reduction in Mortality or Progression to Severe Disease in Prospective Studies

  5. Effective and Investigational Pharmacological Treatments (WHO Diagram / NIH Diagram)
    1. Corticosteroids
      1. IDSA Recommendations on the Use of Dexamethasone in COVID-19
      2. Dexamethasone Appears to the Reduce Mortality in Severe and Critical COVID-19
      3. Corticosteroids May Increase Mortality in COVID-19 Patients with a History of Asthma.
    2. Favipiravir
      1. Clinical Trials
      2. Preliminary Findings
    3. Famotidine
      1. Clinical Trials
      2. IDSA Recommendations on the Use of Famotidine in COVID-19
      3. Preliminary Findings
    4. Ivermectin
      1. NIH Recommendations on the Use of Ivermectin for the Treatment of COVID-19
      2. Clinical Trials
      3. Preliminary Findings
    5. Other
      1. Almitrine
      2. Baricitinib
      3. Camostat Mesylate
      4. Estradiol
      5. Inhaled Interferon Beta-1a

  6. Ineffective Pharmacological Treatments
    1. WHO SOLIDARITY Trial
      1. Remdesivir, Hydroxychloroquine, Lopinavir, and Interferon Appear to Have Little or No Effect on Hospitalized COVID-19, As Indicated by Overall Mortality, Initiation of Ventilation, and Duration of Hospital Stay
    2. Remdesivir
      1. WHO Recommends Against the Use of Remdesivir in COVID-19
      2. Remdesivir Does Not Appear to Improve Clinical Status or Outcome in COVID-19
    3. Hydroxychloroquine / Chloroquine
      1. NIH Recommends Against the Use of Hydroxychloroquine or Chloroquine in COVID-19
      2. Contextual Commentary: Of Chloroquine and COVID-19
          In past research, chloroquine has shown in vitro activity against many different viruses, but no benefit in animal models. Chloroquine has been proposed several times for the treatment of acute viral diseases in humans without success.
      3. Hydroxychloroquine and Cholorquine are Ineffective as Prophylaxis for or the Treatment of COVID-19 and are Cardiotoxic
    4. Tocilizumab
      1. NIH Recommends Against the Use of Anti-IL-6 Receptor Monoclonal Antibodies (Tocilizumab, Sarilumab, Siltuximab) for the Treatment of COVID-19
      2. COVACTA Trial: No Improvement in Clinical Status of COVID-19 Associated Pneumonia or Reduction of Mortality (Roche Press Release)
      3. Tocilizumab Appears Ineffective in Preventing Intubation or Death in Hospitalized Patients
    5. Lopinavir–Ritonavir
      1. NIH Recommends Against the Use of Lopinavir/Ritonavir in COVID-19
      2. Lopinavir-Ritonavir is Ineffective in the Treatment of COVID-19
Share

1 Response

  1. Munir Hazbun MD says:

    Our published report support the use of Methylprednisolone in severe COVID 19 respiratory failure. We learned that higher doses allowed to rescued several patients. We have not need prone position since. The illness is protracted but with a mortality of about 15% with comprehensive care that is broad, including anti-coagulation, lung recruitment strategies among state of the art critical care .
    https://journals.lww.com/ccejournal/pages/articleviewer.aspx?year=2020&issue=06000&article=00023&type=Fulltext&context=LatestArticles

Leave a Reply

Your email address will not be published. Required fields are marked *